DALLIO, MARCELLO
 Distribuzione geografica
Continente #
NA - Nord America 270
AS - Asia 132
EU - Europa 124
AF - Africa 7
SA - Sud America 2
Totale 535
Nazione #
US - Stati Uniti d'America 266
SG - Singapore 71
IT - Italia 56
CN - Cina 35
UA - Ucraina 29
NL - Olanda 16
FI - Finlandia 9
PH - Filippine 8
VN - Vietnam 8
CI - Costa d'Avorio 7
MY - Malesia 7
CA - Canada 4
GB - Regno Unito 4
DE - Germania 3
IN - India 3
RU - Federazione Russa 3
PE - Perù 2
SE - Svezia 2
FR - Francia 1
IE - Irlanda 1
Totale 535
Città #
Singapore 63
Chandler 46
Ashburn 29
Santa Clara 28
Millbury 15
Amsterdam 14
Beijing 13
Napoli 11
Des Moines 9
Helsinki 9
Dong Ket 8
Lawrence 8
Manila 8
Naples 8
Kuala Lumpur 7
Nanjing 6
Shanghai 6
Murfreesboro 4
Pomigliano D'arco 4
Boston 3
Princeton 3
Redwood City 3
Seattle 3
The Dalles 3
Gualtieri 2
Lima 2
Mountain View 2
Nanchang 2
Ottawa 2
Pune 2
Sorrento 2
Toronto 2
Vittorio Veneto 2
Andover 1
Bari 1
Bologna 1
Caivano 1
Dallas 1
Dublin 1
Fairfield 1
Falkenstein 1
Frankfurt am Main 1
Frattamaggiore 1
Hebei 1
Hyderabad 1
Kronberg 1
London 1
Los Angeles 1
Melito Di Napoli 1
Moscow 1
Palermo 1
Pisticci 1
Riccione 1
Saint-Denis 1
San Diego 1
San Giorgio di Piano 1
San Giuseppe Vesuviano 1
Seriate 1
Taranto 1
Tianjin 1
Washington 1
Waynesboro 1
Wilmington 1
Woodbridge 1
Totale 360
Nome #
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 83
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 69
ANTIOXIDANT EFFECTS OF SILYBIN, SILYBINPHOSPHATIDYLCHOLINE COMPLEX, AND DERIVATIVES OF SILIBININ ON IN VITRO CULTURED CELLS DAMAGED BY OXIDATIVE STRESS 63
Urotensin II receptor expression in patients with ulcerative colitis: a pilot study 37
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 33
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 33
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study 31
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 29
Posters 28
Silybin-induced apoptosis occurs in parallel to the increase of ceramides synthesis and mirnas secretion in human hepatocarcinoma cells 28
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 23
Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study 20
The bisphenol a induced oxidative stress in non-alcoholic fatty liver disease male patients: A clinical strategy to antagonize the progression of the disease 20
Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study 18
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial 15
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology 14
Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma 10
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 9
Percutaneous endoscopic gastrostomy for critically ill patients in a general intensive care unit 7
Totale 570
Categoria #
all - tutte 3.083
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.083


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202022 0 0 0 0 0 0 1 2 4 8 4 3
2020/202168 0 3 3 5 14 5 5 1 6 16 1 9
2021/202255 1 0 2 1 1 2 1 1 3 8 7 28
2022/2023123 11 3 3 4 20 17 5 8 27 19 3 3
2023/2024125 6 20 14 12 3 21 0 11 6 3 17 12
2024/2025139 22 27 8 10 19 53 0 0 0 0 0 0
Totale 570